| Laura Ann Martin, CRNA | |
|
2010 59th St W, Ste 5600, Bradenton, FL 34209-4616 | |
| (941) 798-3524 | |
| Not Available |
| Full Name | Laura Ann Martin |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 27 Years |
| Location | 2010 59th St W, Bradenton, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003838558 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | ARNP3212572 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doctors Hospital Of Sarasota | Sarasota, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Coral Anesthesia Associates, Inc | 5193986131 | 46 |
News Archive
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
New software, which will allow GP practice managers to improve healthcare for chronic illnesses including strokes, Alzheimer's and cancer, will be unveiled by scientists from The University of Manchester next week (13 & 14 March).
WuXi PharmaTech today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally.
A surprise discovery - that calorie-burning brown fat can be produced experimentally from muscle precursor cells in mice - raises the prospect of new ways to fight obesity and overweight, say scientists from Dana-Farber Cancer Institute.
The double-blind, placebo-controlled, parallel-group study (Study 306) showed that perampanel was well-tolerated and effective in reducing median seizure frequency and increasing responder rates, the primary outcome measures in the United States and European Union, respectively. The findings were highly statistically significant in 4 mg and 8 mg doses compared to placebo.
› Verified 6 days ago
| Entity Name | Lakewood Ranch Anesthesia Pl |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932157989 PECOS PAC ID: 9638074248 Enrollment ID: O20031205000181 |
News Archive
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
New software, which will allow GP practice managers to improve healthcare for chronic illnesses including strokes, Alzheimer's and cancer, will be unveiled by scientists from The University of Manchester next week (13 & 14 March).
WuXi PharmaTech today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally.
A surprise discovery - that calorie-burning brown fat can be produced experimentally from muscle precursor cells in mice - raises the prospect of new ways to fight obesity and overweight, say scientists from Dana-Farber Cancer Institute.
The double-blind, placebo-controlled, parallel-group study (Study 306) showed that perampanel was well-tolerated and effective in reducing median seizure frequency and increasing responder rates, the primary outcome measures in the United States and European Union, respectively. The findings were highly statistically significant in 4 mg and 8 mg doses compared to placebo.
› Verified 6 days ago
| Entity Name | West Florida Anesthesia Consultants, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992753941 PECOS PAC ID: 3375440076 Enrollment ID: O20031218000799 |
News Archive
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
New software, which will allow GP practice managers to improve healthcare for chronic illnesses including strokes, Alzheimer's and cancer, will be unveiled by scientists from The University of Manchester next week (13 & 14 March).
WuXi PharmaTech today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally.
A surprise discovery - that calorie-burning brown fat can be produced experimentally from muscle precursor cells in mice - raises the prospect of new ways to fight obesity and overweight, say scientists from Dana-Farber Cancer Institute.
The double-blind, placebo-controlled, parallel-group study (Study 306) showed that perampanel was well-tolerated and effective in reducing median seizure frequency and increasing responder rates, the primary outcome measures in the United States and European Union, respectively. The findings were highly statistically significant in 4 mg and 8 mg doses compared to placebo.
› Verified 6 days ago
| Entity Name | Coral Anesthesia Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417221771 PECOS PAC ID: 5193986131 Enrollment ID: O20120418000314 |
News Archive
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
New software, which will allow GP practice managers to improve healthcare for chronic illnesses including strokes, Alzheimer's and cancer, will be unveiled by scientists from The University of Manchester next week (13 & 14 March).
WuXi PharmaTech today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally.
A surprise discovery - that calorie-burning brown fat can be produced experimentally from muscle precursor cells in mice - raises the prospect of new ways to fight obesity and overweight, say scientists from Dana-Farber Cancer Institute.
The double-blind, placebo-controlled, parallel-group study (Study 306) showed that perampanel was well-tolerated and effective in reducing median seizure frequency and increasing responder rates, the primary outcome measures in the United States and European Union, respectively. The findings were highly statistically significant in 4 mg and 8 mg doses compared to placebo.
› Verified 6 days ago
| Entity Name | Lakewood Ambulatory Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013313733 PECOS PAC ID: 3678896354 Enrollment ID: O20150105001092 |
News Archive
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
New software, which will allow GP practice managers to improve healthcare for chronic illnesses including strokes, Alzheimer's and cancer, will be unveiled by scientists from The University of Manchester next week (13 & 14 March).
WuXi PharmaTech today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally.
A surprise discovery - that calorie-burning brown fat can be produced experimentally from muscle precursor cells in mice - raises the prospect of new ways to fight obesity and overweight, say scientists from Dana-Farber Cancer Institute.
The double-blind, placebo-controlled, parallel-group study (Study 306) showed that perampanel was well-tolerated and effective in reducing median seizure frequency and increasing responder rates, the primary outcome measures in the United States and European Union, respectively. The findings were highly statistically significant in 4 mg and 8 mg doses compared to placebo.
› Verified 6 days ago
| Entity Name | Anesthesia Dynamics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073001012 PECOS PAC ID: 3779832530 Enrollment ID: O20190820001117 |
News Archive
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
New software, which will allow GP practice managers to improve healthcare for chronic illnesses including strokes, Alzheimer's and cancer, will be unveiled by scientists from The University of Manchester next week (13 & 14 March).
WuXi PharmaTech today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally.
A surprise discovery - that calorie-burning brown fat can be produced experimentally from muscle precursor cells in mice - raises the prospect of new ways to fight obesity and overweight, say scientists from Dana-Farber Cancer Institute.
The double-blind, placebo-controlled, parallel-group study (Study 306) showed that perampanel was well-tolerated and effective in reducing median seizure frequency and increasing responder rates, the primary outcome measures in the United States and European Union, respectively. The findings were highly statistically significant in 4 mg and 8 mg doses compared to placebo.
› Verified 6 days ago
| Entity Name | Premier Anesthesia Of Florida Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790330694 PECOS PAC ID: 4385975556 Enrollment ID: O20191021000304 |
News Archive
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
New software, which will allow GP practice managers to improve healthcare for chronic illnesses including strokes, Alzheimer's and cancer, will be unveiled by scientists from The University of Manchester next week (13 & 14 March).
WuXi PharmaTech today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally.
A surprise discovery - that calorie-burning brown fat can be produced experimentally from muscle precursor cells in mice - raises the prospect of new ways to fight obesity and overweight, say scientists from Dana-Farber Cancer Institute.
The double-blind, placebo-controlled, parallel-group study (Study 306) showed that perampanel was well-tolerated and effective in reducing median seizure frequency and increasing responder rates, the primary outcome measures in the United States and European Union, respectively. The findings were highly statistically significant in 4 mg and 8 mg doses compared to placebo.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura Ann Martin, CRNA Po Box 552106, Tampa, FL 33655-2106 Ph: () - | Laura Ann Martin, CRNA 2010 59th St W, Ste 5600, Bradenton, FL 34209-4616 Ph: (941) 798-3524 |
News Archive
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
New software, which will allow GP practice managers to improve healthcare for chronic illnesses including strokes, Alzheimer's and cancer, will be unveiled by scientists from The University of Manchester next week (13 & 14 March).
WuXi PharmaTech today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally.
A surprise discovery - that calorie-burning brown fat can be produced experimentally from muscle precursor cells in mice - raises the prospect of new ways to fight obesity and overweight, say scientists from Dana-Farber Cancer Institute.
The double-blind, placebo-controlled, parallel-group study (Study 306) showed that perampanel was well-tolerated and effective in reducing median seizure frequency and increasing responder rates, the primary outcome measures in the United States and European Union, respectively. The findings were highly statistically significant in 4 mg and 8 mg doses compared to placebo.
› Verified 6 days ago
Carly Provan, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 8000 State Road 64 E, Bradenton, FL 34212 Phone: 941-792-1404 | |
Cynthia Chandler Gibson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7118 Hawks Harbor Cir, Bradenton, FL 34207 Phone: 941-350-2039 | |
Mr. Steven Stanley Walther, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 6015 Pointe West Blvd, Bradenton, FL 34209 Phone: 941-792-1404 Fax: 941-761-0712 | |
Anthony Eleuterio Marchiano, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 6640 Anchor Loop, Apt 108, Bradenton, FL 34212 Phone: 941-567-6926 Fax: 941-567-6926 | |
Chasity Kentros, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2010 59th St W, #4650, Bradenton, FL 34209 Phone: 941-798-3524 | |
Kasey Allen Spivey, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 206 2nd St E, Bradenton, FL 34208 Phone: 941-524-9113 |